|
Draft Genetic Test Review Cystic
Fibrosis Master
List of References MASTER
LIST OF REFERENCES 96, 1997, 1998, 1999, 2000)
College of American Pathologists, Northfield, IL. American College of Obstetricians and
Gynecologists. The best
possible defense position. ACOG
Department of Professional Liability, May 1985 Armstrong DS, Grimwood K, Carzino R, Carlin J, Olinsky A, Phelan PD.
1995. Lower
respiratory tract infection and inflammation in infants with newly
diagnosed cystic fibrosis. BMJ
310:1570-1572.
Asch
DA, Hershey JC, Dekay ML, Pauly MV, Patton JP, Jedrziewski MK, Frei F,
Giardine R, Kant JA, Mennuti MT. 1998, Carrier screening for cystic fibrosis: costs and clinical
outcomes. Med Decis Making 18:202-212. Beech
R, Bekker. 1996.
Planning the development of cystic fibrosis gene carrier
screening. J
Health Serv Res Policy 1:81-92. Bovicelli
L, Rizzo N, Montacuti V, Morandi R.
1986. Transabdominal
vs transcervical routes for chorionic villus
. Lancet
ii:290. Bradley L, Johnson D, Chaparro C, Robertson N, Ferrie R. 1997. A multiplex ARMS test for 10 cystic fibrosis (CF) mutations: Evaluation in a prenatal CF screening program. Genet Test 2:337-341. Bradley
LA, Johnson DD, Doherty RA, Palomaki GE, Haddow JE.
1998. Routine
prenatal cystic fibrosis screening in primary care offices.
Am J Hum Genet
63:A13. Bradley LA, Johnson DD, Palomaki GE, Haddow JE, Robertson NH, Ferrie RM. 1998 J Med Screen 5:34-36. Brambati
B, Terzian E, Tognoni G. 1992.
Randomized clinical trial of transabdominal vs transcervical
chorionic villus sampling methods. Prenat Diagn 11:285-293. Brambati
B, Anelli MC, Tului L. 1996. Prenatal cystic fibrosis screening in a low-risk population
undergoing chorionic villus sampling for fetal karyotyping. Clin Genet
50:23-27.Brock DJH.
1996. Prenatal screening for cystic fibrosis: 5 years’ experience
reviewed. Lancet 347:148-150. Brock
DJH. 2000.
Cystic fibrosis. In:
Antenatal and Neonatal Screening.
Second Edition. Wald
N & Leck I (eds.). Oxford
University Press: London, pp. 325-349. Bronstein MN, Sokol RJ, Abman SH, Chatfield BA, Hammond KB, Hornbridge KM,
et al. 1992. Pancreatic
insufficiency, growth and nutrition in infants identified by newborn
screening as having cystic fibrosis.
J Pediatr 120:533-540. Cho
MK, Arruda M, Holtzman NA. 1997. Educational material about genetic tests:
Does it provide key information for patients and practitioners?
Am J Med Genet 73:314-320. Clayton
EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell PW, Phillips JA. 1995. Teaching
about cystic fibrosis carrier screening by using written and video
information.
Am J Hum Genet 57:171-281. Couper RTL, Corey M, Moore DJ, Fisher J, Forstner GG, Durie PR.
1992. Decline of
exocrine pancreatic function in cystic fibrosis patients with pancreatic
sufficiency. Pediatr
Res 32:170-182. Coutts JAP, Docherty JG, Carachi R, Evans TJ. 1997. Clinical
course of patients with cystic fibrosis presenting with meconium ileus.
Br J Surg
84:555. Cuckle HS, Richardson GA, Sheldon TA, Quirke P. 1994. Cost effectiveness of antenatal screening for cystic fibrosis. BMJ 311:1460-1464. Cuckle
H, Quirke P, Sehmi I, Lewis F, Murray J, Cross D, Cuckle P, Ozols B.
1996. Antenatal
screening for cystic fibrosis. Br J Obstet Gynaecol 103:795-799. Cunningham
JC, Taussig LM. 1999. In: An Introduction to
Cystic Fibrosis for Patients and Families.
Cystic Fibrosis Foundation, p. 99. Cuppens
H, Cassiman JJ. 1995.
A quality control study of CFTR mutation screening in 40
different European laboratories. The
European Concerted Action on Cystic Fibrosis.
Eur J Hum Genet 3:235-245. Doak
C, Doak L, Root J. 1995.
Teaching patients with low literacy skills. JB Lippincott. Dequeker E, Cassiman J. 2000. Genetic proficiency testing in diagnostic laboratories – quality control is the message. Am J Hum Genet 67:A274. Dequeker E, Cassiman
JJ. 2000.
Genetic testing and quality control in diagnostic laboratories. Nat
Genet 25:259-260. Dequeker E, Cuppens
H, Dodge J, Estivill X, Goossens M, Pignatti PR, Scheffer H, Schwartz M,
Schwarz M, Tummler B, Cassiman JJ.
2000. Recommendations
for the quality improvement of genetic testing in cystic fibrosis.
European Concerted Action on Cystic Fibrosis.
Eur J Hum Genet 8
(suppl. 2): S2-24. Doherty
RA, Palomaki GE, Kloza EM, Erickson JL, Dostal DA, Haddow JE.
1994. Prenatal
screening for cystic fibrosis. Lancet 343:172. Doherty
RA, Palomaki GE, Kloza EM, Erickson JL, Haddow JE.
1996. Couple-based
prenatal screening for cystic fibrosis in primary care settings.
Prenat Diagn
16:397-404. Donaldson
C, Shackley P, Abdalla M, Miedzybrodzka Z.
1995. Willingness to
pay for antenatal screening for cystic fibrosis.
Health Econ 4:439-452. Donaldson
C, Shackley P, Abdalla M. 1997.
Using willingness to pay to value close substitutes: carrier
screening for cystic fibrosis revisited.
Health Econ
6:145-159. Elles
R. 1997.
An overview of clinical molecular genetics. Mol Biotechnol
8:95-104. Eng
CM, Schechter C, Robinowitz J, Fulop G, Burgert T, Levy B, Zinberg R,
Desnick RJ. 1997.
Prenatal genetic carrier testing using triple disease screening.
JAMA
278:1268-1272. Fog Index can be computed at http://www.fpd.finop.umn.edu/groups/ppd/documents/information/writing_tips.cfmFirth
HV, Boyd PA, Chamberlain P, MacKenzie IZ, Lindenbaum RH, Huson SM. 1991. Severe
limb abnormalities after chorion villus sampling at 56-66 days
gestation. Lancet
337:762-763. Fry
E. Fry’s readability
graph: clarifications, validity, and extensions to level 17. J
Read 1977:242-252. Gaskin KJ, Gurwitz D, Durie P, Corey M, Levison H, Forstner G.
1982. Improved
respiratory prognosis in patients with cystic fibrosis and normal fat
absorption. J Pediatr 100:857-862. Gasparini P, Arbustini E, Restagno, Zelante I, Stanziale P, Gatta L, Sbaiz L, Sedita AM, Banchieri N, Sapone L, Fiorucci GC, Brinson E, Shulse E, Rappaport E, Fortina P. 1999. Analysis of 31 CFTR mutations by polymerase chain reaction/oligonucleotide ligation assay in a pilot screening of 4476 newborns for cystic fibrosis. J Med Screen 6:67-69. Genetic testing under the clinical laboratory improvement amendments. 2000. Federal Register;65:24928-24934 Ginsberg
G, Blau H, Kerem E, et al. 1994. Cost-benefit analysis of a national screening programme for
cystic fibrosis in an Israeli population.
Health Economics
3:5-23. Gosden
C, Tabor A, Leck I, Grant A, Alfirevic Z, Wald N. (2000).
Amniocentesis and chorionic villus sampling. In: Antenatal & Neonatal Screening. 2nd Edition.
Wald & Leck (eds), Oxford University Press, pp. 470-516. Grant AM. 1992. Transabdominal versus transcervical chorion villus sampling. In: Oxford Database of Perinatal Trials, version 1.2, Disk issue 7, (ed. I Chalmers), record no 6005. Grody WW, Dunkel-Schetter C, Tatsugawa ZH, Fox MA, Fang CY, Cantor RM, Novak JM, Bass HN, Crandall BF. 1997. PCR-based screening for cystic fibrosis carrier mutations in an ethnically diverse pregnant population. Am J Hum Genet 60:935-947. Grody W, Desnick R, Carpenter N, Noll W. 1998. Diversity of cystic fibrosis mutation-screening practices. Am J Hum Genet 62:1252-1254. Grody W, Pyeritz R. 1999. Report card on molecular genetic testing: room for improvement? JAMA 281:845-847. Grody
WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ. 2001. Laboratory
standards and guidelines for population-based cystic fibrosis carrier
screening. Genet Med 3:149-54. Grody WW, Desnick RJ. 2002. Cystic fibrosis population carrier screening: here at last – are we ready? Genet Med 3:88-91. Grubman SA, Fang SL, Mulberg AE, Perrone RD, Rogers LC, Lee DW, et
al. 1995.
Correction of the cystic fibrosis defect by gene complementation
in human intrahepatic biliary epithelial cell lines.
Gastroenterology
108:584-592. Gutman
S. 1999.
The role of Food and Drug Administration regulation of in vitro
diagnostic devices-Applications to genetic testing. Clin Chem
45:746-749. Haddow
JE, Bradley LA, Palomaki GE, Doherty RA, Bernhardt BA, Brock DJH, et
al. 1999a.
Issues in implementing prenatal screening for cystic fibrosis:
Results of a working conference. Genet
Med 1:129-135. Haddow
JE, Bradley LA, Palomaki GE, Doherty RA, Bernhardt BA, Brock DJH, et al. 1999b.
Issues in implementing prenatal screening for cystic fibrosis:
Results of a working conference. J Med Screen 6:60-66. Haddow
JE, Palomaki GE, Bradley LA, Doherty RA.
1998. Screening for
cystic fibrosis. JAMA
279:1068. Harris
H, Scotcher D, Hartley N, Wallace A, Craufurd D, Harris R.
1993. Cystic
fibrosis carrier testing in early pregnancy by general practitioners. BMJ
306:1580-1583. Harris
H, Scotcher D, Hartley N, Wallace A, Craufurd D, Harris R.
1996. Pilot study of
the acceptability of cystic fibrosis carrier testing during routine
antenatal consultations in general practice.
Br J Gen Pract 46:225-227. Hartley
NE, Scotcher D, Harris H, Williamson P, Wallace A, Craufurd D, Harris R.
1997. The uptake and
acceptability to patients of cystic fibrosis carrier testing offered in
pregnancy by the GP. J
Med Genet 34:459-464. Hillyard
S. 2001.
Cystic fibrosis. Genetically
programmed to self-destruct. Lancet
358:Suppl:S20. Hofgartner W, Tait J. 1999. Frequency of problems during clinical molecular-genetic testing. Am J Clin Pathol 112:14-21. Hofgartner
W, Tait J. 1999.
Characteristics of clinical molecular-genetic testing
laboratories in the United States.
Clin Chem 45:1288-1290. Holloway
S, Brock DJH. 1994.
Cascade testing for the identification of carriers of cystic
fibrosis. J Med Screen 1:159-164. Holmes
LB, Pyeritz RE (for the Clinical Practice Committee of the American
College of Medical Genetics). 1998.
Screening for cystic fibrosis.
JAMA
279:1068-1069. Holtzman NA, Watson MS. 1997. Promoting Safe and Effective Genetic Testing in the United States. Final report of the Task Force on Genetic Testing. http://biotech.law.lsu.edu/research/fed/tfgt/ , pp. 1-72. Jung
U, Urner U, Grade K, Coutelle C. 1994.
Acceptability of carrier screening for cystic fibrosis during
pregnancy in a German population. Hum
Genet 94:19-24. Kerem
B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A,
Buchwald M, Tsui LC. 1989.
Identification of the cystic fibrosis gene: genetic analysis.
Science
245:1073-1080. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DWH.
1995. Early
pulmonary inflammation in infants with cystic fibrosis.
Am J Respir Crit Care Med
151:1075-1082. Lanng S, Thorsteinsson B, Lund-Andersen C, Nerup J, Schiøtz, Koch C.
1994. Diabetes
mellitus in Danish cystic fibrosis patients: prevalence and late
diabetic complications. Acta
Paediatr 83:72-77. Leist JC, Kristoco RE. 1990. The changing paradigm for continuing medical education: impact of information on the teachable moment. Bull Med Libr Assoc 78:173-179. Lieu
TA, Watson SE, Washington AE. 1994.
The cost-effectiveness of prenatal carrier screening for cystic
fibrosis. Obstet
Gynecol 84:903-912. Lippman
A, Tomkins DJ, Shine J, Hamilton JL.
1992. Canadian
multicentre randomised clinical trial of chorionic villus sampling and
amniocentesis: final report. Prenat
Diagn 12:385-476. Littlewood JM. 1992.
Gastrointestinal complications in cystic fibrosis.
J R Soc Med 85
(suppl 18):13-19.
Livingstone
J, Axton RA, Gilfillan A, Mennie M, Compton M, Liston WA, Calder AA,
Gordon AJ, Brock DJH. 1994. Antenatal screening for cystic fibrosis: a trial of the
couple model. BMJ
308:1459-1462. Loader
S, Caldwell P, Kozyra A, Levenkron JC, Boehm CD, Kazazian HH Jr., Rowley
PT. 1996.
Cystic fibrosis carrier population screening in the primary care
setting. Am J Hum Genet 59:234-247. Loc, H, Adair S, Mathison, Abedor AJ, Griffin S. Practical Evaluation of Public Health Programs. Public Health Training Network, Centers for Disease Control, Atlanta, Georgia http://www.phppo.cdc.gov/phtn/Pract-Eval/workbook.asp Loeben
GL, Marteau TM, Wilfond BS. 1998.
Mixed Messages: Presentation of information in cystic
fibrosis-screening pamphlets. Am
J Hum Genet 63:1181-1189. Malfoot A, Dab I. 1991.
New insights on gastro-oesophageal reflux in cystic fibrosis by
longitudinal follow-up. Arch
Dis Child. 66:1339-1345. Marteau
T, Dundas R, Axworthy D. 1997.
Long-term cognitive and emotional impact of genetic testing for
carriers of cystic fibrosis: the effects of test result and gender.
Health Psych 16:51-62. Maurage C, Lenaerts C, Weber AM, Brochu P, Yousef I, Roy CC.
1989. Meconium ileus
and its equivalent as a risk factor for the development of cirrhosis: an
autopsy study in cystic fibrosis. J Pediatr Gastroenterol
Nutr 9:17-20. McGovern
M, Benach M, Wallenstein S, Desnick R, Keenlyside R.
1999. Quality
assurance in molecular genetic testing laboratories.
JAMA 281:835-840. Mennie
ME, Gilfillan A, Compton M, Curtis L, Liston WA, Pullen I, Whyte DA,
Brock DJ. 1992.
Prenatal screening for cystic fibrosis.
Lancet
340:214-216. Mennie
ME, Liston WA, Brock DJH. 1992. Prenatal cystic fibrosis carrier testing: designing an
information leaflet to meet the specific needs of the target population.
J Med Genet
29:308-312. Mennuti
M, Thomson E, Press N. 1999. Screening for cystic fibrosis carrier state.
Obstet Gynecol 93:456-461. Meyers
MF, Bernhardt BA, Tambor ES, Holtzman NA.
1994. Involving
consumers in the development of an educational program for cystic
fibrosis carrier screening. Am
J Hum Genet 54:719-726. Miedzybrodzka
ZH, Hall MH, Mollison J, Templeton A, Russell IT, Dean JCS, Kelly KF,
Marteau TM, Haites NE. 1995. Antenatal screening for carriers of cystic fibrosis:
randomised trial of stepwise v
couple screening. BMJ
310:353-357. Morris
JK, Oppenheimer PM. 1995. Cost comparison of different methods of screening for cystic
fibrosis. J Med Screen 2:22-27. Murphy JL, Wooton SA, Bond SA, Jackson AA. 1991. Energy
content of stools in healthy normal controls and patients with cystic
fibrosis. Arch
Dis Child 66:495-500. Murray
J, Cuckle H, Taylor G, Littlewood J, Hewison J.
1999. Screening for
cystic fibrosis. Health
Technol Assess
3:1-104. Murray
J, Cuckle H. 2001.
Cystic fibrosis and fragile X syndrome: the arguments for
antenatal screening. Comb Chem High Throughput Screen
4:265-272.
NCCLS. Molecular diagnostic methods for genetic diseases; approved guideline. MM1-A Vol.20 No.7, 2000. Neglia JP, FitzSimmons SC, Maisonneuve P, Schöni MH, Schöni-Affloter F,
Corey M, et al.
1995. The risk of
cancer among patients with cystic-fibrosis.
N Engl J Med
332:494-499. New
York State Department of Health, Clinical Laboratory Evaluation Program,
Laboratory Standards Rev 9/00 ( http://www.wadsworth.org/labcert/index.html
). Neumaier
M, Braun A, Wagener N. 1998. Fundamentals of quality assessment of molecular amplification
methods in clinical diagnosis. International
Federation of Clinical Chemistry Scientific Division Committee on
Molecular Biology Techniques. Clin
Chem 44:12-26. NIH
Consensus Development Conference Statement.
Genetic testing for cystic fibrosis.
Available at http://consensus.nih.gov/cons/106/106_statement.htm .
Accessed June 3, 1997. Notice
of Intent; Genetic testing under the clinical laboratory improvement
amendments. 2000 Federal Register
65:24928-34. Ornoy A, Arnon J, Katznelson D, Granat M, Caspi B, Chemke A.
1987. Pathological
confirmation of cystic fibrosis in the fetus following prenatal
diagnosis. Am
J Med Genet 28:935-947. Padoan R, Marzano MT, Colombo C, Genoni S, Corbetta C, Seia M, et
al. 1997.
Genotype prognosis and clinical follow-up of cystic fibrosis
patients with meconium ileus or neonatal intestinal obstruction
[abstract]. Proceedings
21st European Cystic Fibrosis Conference (EWGCF), 157. Palomaki
GE, Knight GJ, McCarthy JE, Haddow JE, Donhowe JM.
1997. Maternal serum
screening for Down syndrome in the United States: A 1995 survey.
Am J Obstet Gynecol
16:1046-1051. Petrou
S, Henderson J, Roberts T, Martin MA.
2000. Recent
economic evaluations of antenatal screening: a systematic review and
critique. J
Med Screen 7:59-73. Rescorla FJ, Grosfield JL, West KJ, Vane DW. 1989. Changing
pattern of treatment and survival of neonates with meconium ileus.
Arch Surg
51:34-48. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z,
Zielenski J, Lok S, Plavsic N, Chou JL, et
al. 1989. Identification of the cystic fibrosis gene: cloning and
characterization of complementary DNA.
Science
245:1066-1073. Robinson R. 1999. Are we failing in molecular genetic testing? Am J Clin Pathol 112:11-13. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R,
Cole JL, Kennedy K, Hidaka N, et
al. 1989.
Identification of the cystic fibrosis gene: chromosome walking
and jumping. Science 245:1059-1065. Rowley
P, Loader S, Levenkron J. 1997.
Issues in genetic testing. Cystic
fibrosis carrier population screening: A review.
Genet Test 1:53-59. Rowley
PT, Loader S, Kaplan RM. 1998. Prenatal screening for cystic fibrosis: An economic
evaluation. Am J Hum Genet 63:1160-1174. Schöni MH, Mainsonneuve P, Schöni-Affloter F, Lowenfels AB.
1996. Cancer risk in
patients with cystic fibrosis: The European data.
J R Soc Med
89 (suppl 27):38-43. Schwartz
M, Brandt NJ, Skovby F. 1993.
Screening for carriers of cystic fibrosis among pregnant women:
A pilot study. Eur J Hum Genet 1:239-244. Schwarz MJ, Malone GM, Haworth A, Cheadle
JP, Meredith AL, Gardner A, Sawyer IH, Connarty M, Dennis N, Seller A, et
al. 1995.
Cystic fibrosis mutation analysis: report from 22 UK regional
genetics laboratories. Hum
Mutat 6:326-333. Schwartz
M. 1999.
Genetic testing and the clinical laboratory improvement
amendments of 1988: present and future.
Clin Chem 45:739-745. Scott-Jupp R, Lama M, Tanner MS. 1991.
Prevalence of liver disease in cystic fibrosis.
Arch Dis Child 66:698-701. Secretary’s
Advisory Committee on Genetic Testing.
Enhancing the oversight of genetic tests: Recommendations of the
SACGT. (http://www4.od.nih.gov/oba/sacgt.htm). Secretary’s
Advisory Committee on Genetic Testing.
Federal Register
65:77631-77633. Smidt-Jensen
S, Permin M, Philip J, Lundsteen C et al.
Randomized comparison of amniocentesis and transabdominal and
transcervical chorionic villus sampling
Lancet, 340: 1237-44. Stenhouse S, Middleton-Price H. Quality assurance in molecular diagnosis. The UK experience. (pp. 341-352). In: Methods in Molecular Medicine: Molecular diagnosis of genetic diseases. Edited by: R. Elles. Humana Press Inc., Totowa, NY. Super
M, Schwartz MJ, Malone G, Roberts T, Haworth A, Dermody G.
1994. Active cascade
screening for carriers of cystic fibrosis gene.
BMJ
308:1462-1468. Tanner MS. 1992.
Liver and biliary problems in cystic fibrosis.
J R Soc Med 85
(suppl 19):20-24. Tabor
A, Philip J, Madsen M, Bang J, Obel E, Norgaard-Pedersen B.
1986. Randomised
controlled trial of genetic amniocentesis in 4606 low risk women.
Lancet
i:1287-1293. Tekfi,
Chafai (1987) Readability Formulas: An Overview, J Docum 43:261-73. The Cystic Fibrosis Genetic Analysis Consortium.
1990. Worldwide
survey of the deltaF508 mutation. Am J Hum Genet
47:354-359. US Congress, Office of Technology Assessment, Cystic Fibrosis and DNA Tests: Implications of carrier screening. OTA-BA-532 (Washington, DC: US Government Printing Office, August 1992). Vintzileos
AM, Ananth CV, Smulian JC, Fisher AJ, Day-Salvatore D, Beazoglou T. 1998. A
cost-effectiveness analysis of prenatal carrier screening for cystic
fibrosis. Obstet Gynecol 91:529-534. Wald
NJ, George LM, Wald NM, Mackenzie IZ.
1993. Couple
screening for cystic fibrosis. Lancet
342:1307-1308. Wald
NJ, George L, Wald N, MacKenzie IZ.
1995. Further
observations in connection with couple screening for cystic fibrosis.
Prenat Diagn 15:589-590. Wald
NJ. 1999.
Biochemical detection of neural tube defects and Down's syndrome.
In: Turnbull's
Obstetrics, 2nd Edition, G. Chamberlain (ed).
Churchill Livingstone, Edinburgh, pp. 195-209. Ward
H, Rodeck C. 1993.
Comparison of amniocentesis and transabdominal and transcervical
chorionic villus sampling. Lancet
341:186-187. Waters DL, Dorney SFA, Gaskin KJ, Grauca MA, O’Halloran M, Wilken B.
1990. Pancreatic
function in infants identified as cystic fibrosis in a neonatal
screening program. N
Engl J Med 322:303-308. Watson
M. 1995.
Current activities involving economic, regulatory, and practice
issues in molecular genetic testing.
Diagn Mol Pathol
4:233-234. Wildhagen
MF, Hilderink HB, Verzijl JG, Verheij JB, Kooij L, Tijmstra T, ten Kate
LP, Habbema JD. 1998.
Costs, effects, and savings of screening for cystic fibrosis gene
carriers. J
Epidemiol Community Health 52:459-467. Wilfond
BS, Fost N. 1992.
The introduction of cystic fibrosis carrier screening into
clinical practical: Policy
considerations. Milbank
Quarterly 70:629-659. Witt
DR, Schaefer C, Hallam P, Wi S, Blumberg B, Fishbach A, Holtzman J,
Kornfeld S, Lee R, Nemzer L, Palmer R.
1996. Cystic
fibrosis heterozygote screening in 5,161 pregnant women.
Am J Hum Genet 58:823-835. Woods
P, Jeffrey B. Teachable
moments. Open University Press, 1996. |
|
Updated on August 13, 2004